Sweeteners Slow Growth of Key Gut Bacteria in Laboratory Studies

Cambridge researchers report that several widely used low-calorie sweeteners can directly interfere with gut bacteria—an effect that becomes more pronounced when sweeteners are combined with other everyday chemicals and pharmaceuticals. In work published in Molecular Systems Biology, the team tested how artificial and natural sweeteners influence the growth of multiple bacterial species commonly found in the digestive tract.

The study is notable because it moves beyond correlations from animal or population studies by asking a more mechanistic question: do sweeteners act passively as they pass through the body, or do they alter microbial biology in direct exposure experiments? The researchers also highlight a real-world complication—people rarely consume sweeteners alone, instead mixing them into foods, drinks, and even medications.

In vitro experiments examined 25 bacterial species spanning beneficial, neutral, and potentially harmful groups. Each species was cultured and exposed individually to 39 commercially used sweeteners. Roughly three quarters altered the growth of at least one bacterium, with some suppressing organisms associated with healthier gut function.

To model combined exposures, the team then tested sweetener–compound pairings with common additives such as caffeine and the flavoring vanillin, alongside drugs including eight medications. The combinations produced more than 100 distinct interaction patterns in which bacterial responses changed relative to sweeteners alone. In 34 cases, the impact intensified; in 68 cases, it weakened.

The most striking interaction involved isosteviol—a sweetener used in industry—and the antidepressant duloxetine. Together, they strongly suppressed Roseburia intestinalis and Parabacteroides merdae, bacteria implicated in digestive health and metabolic regulation.

Because gut ecosystems behave like communities rather than isolated strains, the researchers also built a synthetic community containing all 25 species. After growth over time, this community showed reduced microbial diversity under the isosteviol–duloxetine combination, alongside shifts in which species expanded or declined.

Further analysis suggested that the altered microbiome function increased toxicity toward host cells and disrupted pathways linked to inflammation and immune responses. While these findings raise concerns, the authors stress the experiments were laboratory-based and not tested in humans.

Overall, the study challenges the idea that low-calorie sweeteners are metabolically neutral in practice. It suggests that sweeteners can directly shape microbial behavior and that drug co-exposure may amplify or redirect those effects, motivating future in vivo and clinical research.